Theranostics 2021; 11(6):2581-2593. doi:10.7150/thno.52366

Review

N6-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

Jinming Li1,2, Lei Liang1,2, Yongzhi Yang1,2, Xinxiang Li1,2, Yanlei Ma1,2✉

1. Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Li J, Liang L, Yang Y, Li X, Ma Y. N6-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction. Theranostics 2021; 11(6):2581-2593. doi:10.7150/thno.52366. Available from https://www.thno.org/v11p2581.htm

File import instruction

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers and one of the leading causes of cancer death. Recent studies have provided evidence that N6-methyladenosine (m6A), the most abundant RNA modifications in eukaryote, performs many functions in RNA metabolism including translation, splicing, storage, trafficking and degradation. Aberrant regulation of m6A modification in mRNAs and noncoding RNAs found in CRC tissues is crucial for cancer formation, progression, invasion and metastasis. Further, m6A regulators and m6A-related RNAs may become promising biomarkers, prognosis predictors as well as therapeutic targets. Here, we review the biological and clinical roles of m6A modification in CRC, and discuss the potential of m6A in clinical translation.

Keywords: colorectal cancer, m6A, RNA modification, cancer progression, cancer treatment